BORDEAUX, France–(BUSINESS WIRE)–Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain disorders, today announces that it has successfully completed all the regulatory non-clinical studies necessary to enter in phase 3 clinical trials AEF0117, the Company’s most advanced signaling specific inhibitor of the CB1 receptor of the endocannabinoid system. AEF0117 is currently tested in a
Source link
